Previous Close | 26.60 |
Open | 27.98 |
Bid | 21.98 x 0 |
Ask | 0.00 x 0 |
Day's Range | 26.32 - 27.98 |
52 Week Range | 10.00 - 223.80 |
Volume | |
Avg. Volume | 1,247,431 |
Market Cap | 55.369M |
Beta (5Y Monthly) | -3.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -23.40 |
Earnings Date | Sep 30, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 220.00 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
SOUTHAMPTON, England, May 16, 2022--Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19.
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that further analysis of its Phase 3 SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco, at the following two sessions: